Join
Live feed
·
PRReleasevia Quantisnow
IMARA Inc. logo

Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

ByQuantisnow·Wall Street's wire, on your screen.
IMRA· IMARA Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMRA (IMARA Inc.) and more on Quantisnow.